Abstract
With the growth of monoclonal antibodies and other proteins as major modalities in the pharmaceutical industry, there has been an increase in pharmacology and toxicity testing of biotherapeutics in animals. Animals frequently mount an immune response to human therapeutic proteins. This can result in asymptomatic anti-drug antibody formation, immune complexes that affect drug disposition and/or organ function such as kidney, cytokine release responses, fatal hypersensitivity, or a range of reactions in between. In addition, an increasing number of oncology therapeutics are being developed that enhance or directly stimulate immune responses by a variety of mechanisms, which could increase the risk of autoreactivity and an autoimmune-like syndrome in animals and humans. When evaluating the risk of biotherapeutics prior to entering the clinic, the nonclinical safety data may include any of these responses and it is critical to understand whether they represent a safety liability for humans. The DruSafe Leadership group of the IQ Consortium conducted a survey of industry to understand sponsors' experiences with these immune reactions in nonclinical studies related to both immunogenicity and pharmacologically-mediated immune perturba...Continue Reading
References
Apr 7, 2009·Regulatory Toxicology and Pharmacology : RTP·Rafael PonceDan Wierda
Nov 17, 2009·The Journal of Allergy and Clinical Immunology·Patrick J BrennanMariana C Castells
Dec 7, 2010·Regulatory Toxicology and Pharmacology : RTP·Mark ZorbasMark Butt
Nov 19, 2013·Toxicologic Pathology·Michael W LeachJoseph C Beyer
Mar 13, 2014·Toxicologic Pathology·Jonathan R HeyenBora Han
Apr 8, 2014·Toxicologic Pathology·Jennifer L RojkoChristopher Horvath
Jan 21, 2015·Journal of Immunological Methods·Cathelijne KloksHishani Kirby
Mar 31, 2015·European Journal of Pharmacology·Peter J K van MeerHenk-Jan Schuurman
Dec 26, 2015·Toxicologic Pathology·Roy KerlinJames Popp
Feb 13, 2016·Frontiers in Immunology·Murli Krishna, Steven G Nadler
Apr 23, 2016·Toxicologic Pathology·Xavier PalazziMidori Yoshida
Apr 4, 2017·Immunology and Allergy Clinics of North America·Sheenal V Patel, David A Khan
Jun 19, 2017·Regulatory Toxicology and Pharmacology : RTP·Sven KronenbergFranziska Regenass
Aug 24, 2017·Toxicologic Pathology·Elisabeth HusarGaurav Tyagi
Apr 17, 2018·Current Opinion in Toxicology·Kirsten M MeaseJanice A Lansita
Aug 31, 2018·Toxicologic Pathology·John L Vahle
May 16, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Changhua JiBernard S Buetow
Jul 12, 2019·Science Translational Medicine·Friederike JönssonPierre Bruhns